EBIM
CLB icon

Eagle Boston Investment Management’s Core Laboratories CLB Stock Holding History

Eagle Boston Investment Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,829
Closed -$230K – 128
2018
Q2 		$230K Buy
+1,829
New +$223K 0.02% 146

Other funds holding CLB

WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Royal London Asset Management
Royal London Asset Management United Kingdom $47.7B AUM 29.41% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eagle Boston Investment Management's CLB Position: Q3 2018 in Review

Eagle Boston Investment Management sold out of Core Laboratories (CLB) in Q3 2018, closing a stake of 1,829 shares — an estimated $230K sold.

Eagle Boston Investment Management first reported a position in CLB in Q2 2018 and held it in 1 quarter. The position peaked at $230K in Q2 2018. 360 funds tracked by Wall St. Rank hold CLB as of Q3 2018.

  • Eagle Boston Investment Management reported no remaining Core Laboratories position as of Q3 2018 after selling out during the quarter.
  • Eagle Boston Investment Management sold 1,829 Core Laboratories shares in Q3 2018, an estimated $230K.
  • Eagle Boston Investment Management first reported a position in Core Laboratories in Q2 2018 and held it in 1 quarter.
  • Eagle Boston Investment Management's Core Laboratories position peaked at $230K in Q2 2018.
  • 360 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2018.

Based on Eagle Boston Investment Management's 13F filing for Q3 2018, filed 8 Nov 2018.